Duke Street Bio

Executive Summary

Duke Street Bio is a UK-based biotechnology company founded in 2021, dedicated to developing next-generation cancer therapies by targeting DNA Damage Repair (DDR) deficiencies and leveraging the immune system. The company's precision medicine platform focuses on tumors with DDR defects, aiming to exploit synthetic lethality and enhance antitumor immunity. Its lead program, a highly selective PARP1 inhibitor, is currently in clinical trials, distinguishing itself from earlier PARP inhibitors by potentially reducing off-target toxicity and improving the therapeutic window. Duke Street's approach addresses a validated mechanism in oncology, with PARP inhibitors already approved for BRCA-mutated cancers, but the company's next-generation inhibitor may expand applicability to a broader patient population.

Upcoming Catalysts (preview)

• Q4 2026Initial clinical data readout from PARP1 inhibitor trial50% success
• H1 2027Strategic partnership or licensing deal for PARP1 inhibitor40% success
• Q2 2026Series B or Series C financing round60% success